Increase of Risperidone Concentration under Chlorprothixene Comedication - A Case Report

 

 Buy Article Permissions and Reprints

Risperidone is known to be metabolized by liver cytochrome P450 isoenzymes (CYP), primarily by CYP2D6 and to a much lesser extent also by CYP3A4, via aliphatic hydroxylation to form its active metabolite 9-hydroxyrisperidone. 9-Hydroxyrisperidone is the major metabolite and contributes equally to the pharmacological actions of risperidone. Therapeutic drug monitoring (TDM) under risperidone treatment refers to the sum of the risperidone and 9-hydroxyrisperidone concentrations as the so-called “active moiety”. Enzyme inhibition is said to have no effect on the concentration of the active moiety [6]. We report on a patient in whom the active moiety turned out to be too high in relation to the dose given. The patient was on risperidone in comedication with chlorprothixene. The concentration ratio of parent drug and active metabolite was increased as well suggesting a metabolic interaction of the two substances via enzyme inhibition.

References

• 1 Bader W, Melchner D, Nonenmacher T, Haen E. Determination of five commonly used antipsychotics in human serum by high-performance liquid chromatography (HPLC) and electrochemical detection.  Pharmacopsychiatry. 2005;  38 42
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Baumann P, Hiemke C, Ulrich S. et al . The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-265
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Greiner C, Haen E. Therapeutic drug monitoring in psychiatry - reference ranges for the dose-concentration relationship.  Psychiatrische Praxis. 2007;  34 90-92
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Haen E. Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen zur Therapieleitung.  Psychopharmakotherapie. 2005;  12 138-143
  PubMedGoogle Scholar
• 5 Haen E, Greiner C, Bader W, Wittmann M. Wirkstoffkonzentrationsbestimmungen zur Therapieleitung - Ergänzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche, submitted to “Der Nervenarzt”.  .
  PubMedGoogle Scholar
• 6 Scordo MG, Spina E, Facciola G. et al . Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.  Psychopharmacology. 1999;  147 300-305
  CrossrefPubMedGoogle Scholar
• 7 Snoeck E, Peer A van, Sack M. et al . Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.  Psychopharmacology. 1995;  122 223-229
  PubMedGoogle Scholar

Correspondence

W. Bader

Clinical Pharmacology, Department of Psychiatry, Psychosomatics and Psychotherapy

University of Regensburg

Universitätsstraße 84

93053 Regensburg

Germany

Phone: +49/941/941 20 83

Fax: +49/941/941 20 65

Email: wolfgang.bader@klinik.uni-regensburg.de